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The first case of coronavirus disease (COVID-19) in 
Finland was confirmed on 29 January 2020. No sec-
ondary cases were detected. We describe the clini-
cal picture and laboratory findings 3–23 days since 
the first symptoms. The SARS-CoV-2/Finland/1/2020 
virus strain was isolated, the genome showing a sin-
gle nucleotide substitution to the reference strain 
from Wuhan. Neutralising antibody response appeared 
within 9 days along with specific IgM and IgG response, 
targeting particularly nucleocapsid and spike proteins.
On 31 December 2019, a cluster of pneumonia cases 
of unknown aetiology was reported in Wuhan, Hubei 
Province, China [1]. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) was isolated by Chinese 
scientists on 7 January 2020. To date, the SARS-CoV-2 
virus causing the coronavirus disease (COVID-19) pan-
demic is spreading throughout the world.
Here we describe the timeline of events around the first 
COVID-19 case imported to Finland, and summarise the 
clinical, molecular and serological data. Successful 
SARS-CoV-2/Finland/1/2020 isolation enabled us to 
use the cytopathic effect (CPE)-based microneutralisa-
tion (MN) assay to detect SARS-CoV-2-specific neutral-
ising antibody levels. Diagnostic serum samples of the 
case and three close contacts were analysed and com-
pared with serum samples from the Finnish population 
collected in 2019.
 
Clinical presentation and laboratory 
confirmation of the case
The first COVID-19 case in Finland was a female Chinese 
tourist in her 30s, who had left Wuhan on 22 January 
and arrived in Finland on 23 January. Her first symp-
toms were a runny nose on 26 January and nausea on 
27 January. Because of high fever (39 °C), weakness 
and cough she sought medical attention on 28 January. 
Suspicion of COVID-19 led to her direct transfer to the 
Lapland Central Hospital in Rovaniemi, where she was 
isolated and sampled on 28 and 29 January for labo-
ratory confirmation of SARS-CoV-2 infection (Figure 1). 
SARS-CoV-2 infection was confirmed from nasopharyn-
geal samples on 29 January by the Helsinki University 
Hospital Laboratory (HUSLAB), and further confirmed 
at the Finnish Institute for Health and Welfare (THL) 
(Table). Both laboratories performed real-time RT-PCR 
testing for three targets: the envelope (E), the RNA-
dependent RNA polymerase (RdRp) and the nucleocap-
sid (N). Primers and probes were based on the Corman 
et al. method [2]. Cycle threshold (Ct) values above 37 
were considered negative.
The case had mild symptoms throughout the isola-
tion period. She was tested PCR-negative in 3 and 4 
February samples and, as considered asymptomatic, 
discharged from hospital on 5 February. One additional 
sample for serology and PCR was taken on 14 and 17 
February, respectively.
Altogether 21 close contacts were identified of whom 
we could reach 17. Fourteen were still in Finland and 
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placed in quarantine for 14 days. Information about 
three close contacts that had left the country was com-
municated to the competent authorities in their respec-
tive countries. For the remaining four close contacts, 
we had no contact details. Two of the 21 close con-
tacts were closely co-exposed and therefore sampled 
on Days 4, 10, 12 and 14 after the first symptoms of 
the index case. Follow-up of all contacts ended on 11 
February without secondary transmission events.
SARS-CoV-2/Finland/1/2020 virus isolation
The SARS-CoV-2 virus SARS-CoV-2/Finland/1/2020 was 
isolated in a biosafety level 3 (BSL-3) laboratory in Vero 
E6 cells from the Day 4 nasopharyngeal swab (NPS) 
and nasopharyngeal aspirate (NPA) specimens (Table). 
The samples were inoculated into the cells for 1 h at 
37 °C and 5% CO2  and fresh culture medium (Eagle›s 
minimum essential medium (EMEM) supplemented 
with 2% fetal bovine serum (FBS), 0.6 μg/mL penicil-
lin, 60 μg/mL streptomycin, 2 mM L-glutamine, 20 mM 
HEPES) were added for incubation. On the 4th day of 
incubation, half of the cultures were blind-passaged 
onto fresh Vero E6 cells and the rest of original pas-
sages were incubated further. After 4 days incubation 
a clear CPE was detected in the NPA-originated pas-
sage 2. The propagation of stock virus was done by 
passaging a low virus dose once again in Vero E6 cells, 
and virus culture was harvested on the 3rd day. Virus 
concentration was followed by RT-PCR. The Ct value for 
virus passage 1 on the 6th day of incubation was 17.65 
and for passage 2 on the 2nd day, before any CPE was 
20.63, whereas those of the NPS specimen remained at 
Ct values between 35 and 36.
SARS-CoV-2/Finland/1/2020 whole-genome 
sequencing 
Nearly the complete coding region of SARS-CoV-2 
(GenBank accession number: MT020781) was 
sequenced from the NPS collected on Day 4 (Table) 
and the complete coding region was sequenced from 
the virus isolate obtained after three passages in Vero 
E6 cells. The virus had 1 nt substitution C21707T com-
pared with the reference strain Wuhan-Hu-1 collected 
in Wuhan China, December 2019 (NC_045512) [3] which 
had led to a histidine to tyrosine (H49Y) substitution in 
the N-terminal domain of the spike glycoprotein.
Antibody response during the SARS-CoV-2 
infection
Serum samples were collected from the index case on 
Days 4, 9, 10 and 20 from onset of the first symptoms 
(Figure 1). Presence of serum IgM and IgG antibodies 
against SARS-CoV-2 was analysed by immunofluores-
cence assays (IFA) based on Vero E6 cells infected 
with passage 4 of the patient’s isolate SARS-CoV-2/
Finland/1/2020 virus and transferred onto microscope 
slides and fixed with acetone (Figure 2). Serum sam-
ples from the index case were serially diluted and incu-
bated for 2 h for IgM and 30 min for IgG. Antibodies 
were visualised with fluorescein isothiocyanate (FITC)-
conjugated anti-human IgM or IgG antibodies. While 
the antibodies were undetectable on Day 4 after onset 
of symptoms, IgG titres rose to 80 and 1,280 and IgM 
titres to 80 and 320 on Days 9 and 20, respectively 
(Table). Random serum samples from staff members of 
the University of Helsinki (n = 19) did not show specific 
binding at dilutions greater than 20 (Figure 2).
Mock- and SARS-CoV2-infected Vero E6 cells collected 
on Day 6 post infection were lysed in Laemmli sample 
Figure 1
Timeline of events around the first COVID-19 case imported to Finland, January–February 2020
Left
Wuhan
Arrived
in Finland
by flight
Onset of 
respiratory
symptoms
Admitted 
to hospital and
isolated
COVID-19
confirmation Asymptomatic
Discharged
from
hospital
High fever,
sought
medical
attention
22 Jan 23 Jan 26 Jan 28 Jan 29 Jan 30 Jan
Most likely period of communicability of the index case 
2 Feb 3 Feb 4 Feb 5 Feb 6 Feb 8 Feb 14 Feb
Sampling of the index case 
Sampling of the close contacts (asymptomatic)
17 Feb
COVID-19: coronavirus disease.
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buffer, and Western blotting (WB) of lysates was per-
formed as described previously [4]. At 1:200 dilution, 
the convalescent serum on Day 20 identified SARS-
CoV2 N, S and E protein bands (Figure 3). At higher 
exposure, all bands were detectable even at 1:1,600 
serum dilution (Figure 3).
SARS-CoV-2-specific neutralising antibody levels were 
measured in duplicate with the MN test in a BSL-3 labo-
ratory. The serum samples were heat-inactivated at 
56 °C for 30 min and 2-fold serially diluted starting from 
1:4 in EMEM supplemented with 2% of heat-inactivated 
FBS and antibiotics. Fifty plaque‐forming units (PFU) 
of the SARS-CoV-2/Finland/1/2020 strain were added 
to the serum dilutions and incubated for 1 h at 37 °C. 
Vero E6 cells (5 × 104/well) were added to the virus–
serum mix, and the mixture was incubated in 96-well 
plates for 4 days at 37 °C with 5% CO2. Neutralisation 
was assessed by CPE. The neutralisation endpoint was 
determined as the 50% endpoint of the serum that 
inhibited the SARS-CoV-2 infection observed by CPE of 
inoculated cells.
Diagnostic serum samples from the index case and 
her three asymptomatic close contacts were studied 
with the MN test. During the acute phase of infection, 
no neutralising antibodies were detected. The patient 
seroconverted for neutralising antibodies between 
Day 4 and 9, with the titre increasing to 160 on Day 20 
(Table). The serum specimens were confirmed not to be 
toxic or infective to the cells as such.
Serum samples taken from the three close contacts 
tested negative in MN test. We also tested serum sam-
ples collected in 2019 from 83 Finnish subjects aged 
4 to 89 years and all tested negative. Sera known to 
be positive for IgG against human coronavirus OC43 
and 229E [5] and rabbit or guinea pig antibody against 
SARS-CoV N protein [6] could not neutralise the virus.
Ethical statement
The investigations were carried out in accordance with 
the General Data Protection Regulation (Regulation 
(EU) 2016/679 and Directive 95/46/EC) and the Finnish 
Personal Data Act (Finlex 523/1999) The Finnish 
Communicable Diseases Act (Finlex 1227/2016) allows 
sampling for diagnostic and surveillance purposes.
The convalescent serum sample was obtained on 14 
February through informed consent of the patient and 
research permits (TYH2018322, TYH2019263) from the 
Helsinki University Hospital Laboratory.
Finnish population serum samples were collected dur-
ing 2019. The study protocol was approved by the Ethics 
Committee of the Department of Medicine, Helsinki 
University Hospital (Permission 433/13/03/00/15).
Table
Laboratory data of the first case of SARS-CoV-2 infection, Finland, January–February 2020
Sampling day 
 
Day since the first symptoms
Specimen PCR done at E RdRp N MN IgM IgG
28 Jan 2020 
 
Day 3
NPS
HUS 
 
THL
ND 
 
30.49
ND 
 
30.48
ND 
 
31.59
NA NA NA
29 Jan 2020 
 
Day 4
NPA
HUS 
 
THL
31.18 
 
27.13
27.56 
 
28.43
28.29 
 
28.73
NA NA NA
NPS
HUS 
 
THL
28.15 
 
29.59
27.13 
 
30.87
28.82 
 
31.78
NA NA NA
Serum
THL 
 
UH
Neg 
 
Neg
Neg 
 
Neg
Neg 
 
Neg
< 4 < 20 < 20
03 Feb 2020 
 
Day 9
NPS
HUS 
 
THL
Neg 
 
Neg
Neg 
 
Neg
Neg 
 
Neg
NA NA NA
Serum UH ND Neg Neg 60 80 80
04 Feb 2020 
 
Day 10
NPS
HUS 
 
THL
Neg 
 
Neg
Neg 
 
Neg
Neg 
 
Neg
NA NA NA
Serum ND ND ND ND 72 160 160
14 Feb 2020 
 
Day 20
Serum UH Neg Neg Neg 160 320 1,280
17 Feb 2020 
 
Day 23
NPS
HUS 
 
THL
Neg 
 
Neg
Neg 
 
Neg
Neg 
 
Neg
NA NA NA
E: envelope protein gene; HUS: Helsinki University Hospital Laboratory; IgG: immunoglobulin G; IgM: immunoglobulin M; MN: 
microneutralisation test; N: nucleocapsid protein gene; NA: not applicable; ND: not done; Neg: negative; NPA: nasopharyngeal aspirate; NPS: 
nasopharyngeal swab; RdRp: RNA-dependent RNA polymerase gene; RT-PCR: reverse-transcription PCR; THL: Finnish Institute for Health and 
Welfare; UH: University of Helsinki.
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Serum samples of University of Helsinki staff members 
were used under informed consent.
Discussion
In the early phase of the COVID-19 outbreak, confirmed 
cases outside China were mostly imported among trav-
ellers from Wuhan [7]. The first case in Finland was 
detected on 29 January among the first imported cases 
in Europe. The case presented mild symptoms without 
pneumonia: runny nose, nausea, high fever, cough, 
muscular weakness and fatigue. No secondary trans-
mission events were detected despite active follow-up 
by the Lapland Hospital district and THL.
As at 17 March 2020, 358 additional laboratory-
confirmed cases of COVID-19 have been detected in 
Finland. Many of them are travel-related (mostly from 
northern Italy and Austria) but there is also local trans-
mission from the travel-related cases. The risk of wide-
spread national community transmission of COVID-19 
infection in the European Union, European Economic 
Area and the United Kingdom in the coming weeks is 
considered high by the European Centre for Disease 
Prevention and Control [8].
The sequence of the viral genome of the patient was 
nearly identical to the reference strain from Wuhan, 
reflecting an early importation from China. Later 
sequence information in Finland (up to 2 March) 
showed clustering with strains circulating in Italy (see 
nextstrain.org/ncov) [9].
Current guidelines from the World Health Organization 
for testing COVID-19 recommend collection of both 
acute and convalescent serum samples from patients 
for serological testing, which can support the iden-
tification of the immune response to a specific viral 
pathogen [10]. The SARS-CoV-2 nucleic acid has been 
found also in anal swabs and blood [11], however we 
did not detect it in serum samples in this case. As yet, 
only limited data are available on antibody responses 
during SARS-CoV-2 infection [11,12]. Further studies 
are needed to better understand the seroprevalence of 
antibodies to different corona viruses in populations 
and the role of these antibodies in the risk of disease.
In accordance with earlier findings [11], we found that 
both IgM and IgG titres were low or undetectable at 
on Day 4 (the second day after admission to hospital) 
yet increasing on Day 9–10, i.e. 5–6 days after the first 
sampling. Using other detection methods beyond IFA 
as well as recombinant antigens and analysing sam-
ples from a larger number of patients will shed more 
light on this. The time of first appearance of anti-SARS-
CoV antibodies has ranged from Day 3 to 42 and Day 5 
to 47 for IgM and IgG antibodies, respectively [13].
The WB of the serum sample collected at convales-
cence showed a prominent response against the N 
and S protein, confirming their role as main candidate 
Figure 2
Immunofluorescence assay of serum samples, COVID-19 
index case, Finland, January–February 2020
COVID-19: coronavirus disease 2019.
Anti-SARS-CoV-2 IgM and IgG antibodies were detectable by 
immunofluorescence assay in samples from Days 9, 10 and 20 
after onset of illness. Both IgM and IgG were found at a titre 
of 80 on Day 9, titres on Day 20 were 320 and 1,280. As an 
example, dilutions 1:20 and 1:160 from the Day 20 sample are 
shown for, respectively, IgM and IgG of the index case. Dilution 
20 shown for the control serum.
Figure 3
Western blot of mock- and SARS-CoV-2 infected Vero E6 
cells using patient serum collected 20 days after onset of 
symptoms, Finland, January–February 2020
Top left panel: total protein staining (Ponceau S) of the 
nitrocellulose membrane before probing. Top right panel: 
strips probed with different dilutions of the patient serum at 
low exposure. Bottom panel: the same membranes individually 
contrasted for higher band intensity. The arrows indicate SARS-
CoV-2 proteins, the labelling assumes that the migration of SARS-
CoV-2 proteins was similar to that of Vero E6-expressed SARS-CoV 
proteins [23]. The bands migrating at ca 110 and 90 kDa probably 
represent S1 and S2, respectively. Marker M: Precision Plus Dual 
Colour Standards (Bio-Rad). The detection was done using Odyssey 
Infrared Imaging System (LI-COR) using goat anti-human IR800 
conjugate at 1:10,000 dilution.
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diagnostic targets for antibody tests. However, the 
patient serum appeared to recognise also the E pro-
tein and the processed S1 and S2 proteins. Although 
WB detects mainly linear epitopes, the strong antibody 
response against the S protein correlated well with the 
results of the MN assay.
Monitoring of the binding antibodies is suggested 
to be a more sensitive method than measuring func-
tional neutralising antibodies for serological detection 
of human coronavirus (hCoV) infections [14]. However, 
hCoV OC43 and 229E samples can also cross-react 
with SARS-CoV ELISA testing [15]. The SARS-CoV-2 CPE-
based MN test using live virus appeared to be very 
specific, while laborious to conduct requiring a BSL-3 
laboratory. An increase of at least 4-fold in the neu-
tralising antibodies indicating a positive response was 
detected at Day 9–10 after the first symptoms and at 
Day 20, the antibody levels were still increasing. Our 
findings indicate that the MN assay is specific for func-
tional SARS-CoV-2 antibodies and could be applied 
in surveillance of population immunity for this virus. 
The assay can be used as confirmatory tool for SARS-
CoV-2 specificity in the development of more accessi-
ble diagnostic tools such as assays based on detecting 
binding antibodies. Previous studies on patients with 
SARS-CoV infection indicated that the median time for 
seroconversion was 20 days, by which time 60–75% 
of patients had IgG against the virus [13,16]. That IgM 
and IgG antibodies were present within 2 weeks from 
the onset of symptoms in our study suggests that early 
convalescent patients may be suitable sources of ther-
apeutic antibodies [17]. In accordance with our finding, 
a recent preprint report on patients admitted to hos-
pital with confirmed SARS-CoV-2 infection in China 
indicated that the median time to seroconversion was 
11–14 days, depending on the immunological assay 
used [18].
No neutralising SARS-CoV-2 antibodies were detected 
in the close contacts nor in the control population 
samples collected during 2019 in Finland. A low prev-
alence (0.21%) of antibodies against Middle East res-
piratory syndrome coronavirus was reported in the 
general population of Qatar [19]. A meta-analysis of 
seroprevalence to SARS-CoV among different human 
populations yielded an overall low seroprevalence 
(0.10%), although it was slightly higher (0.23%) among 
healthcare workers and others who had close contact 
with SARS patients [20]. Binding and neutralising HCoV 
antibodies were found to be higher in older adults [14]. 
In total 97% and 99% of serum samples from healthy 
adults had antibodies to HCoV-229E and HCoV-OC43, 
respectively [21], and 75% and 65% of the children in 
the age group 2.5–3.5 years were found to be seroposi-
tive for, respectively, HCoV-NL63 and HCoV-229E [22].
While it has been suggested that the late serocon-
version in most SARS patients reduces the value of 
serological assays during the incubation and initial 
phases of SARS [13], serological testing is suggested 
for the confirmation of a SARS CoV-2 infection [11]. 
After understanding better the kinetics, specificity 
and sensitivity of the assays in development, the sero-
logical testing may help contact tracing of clusters and 
have a role in diagnosing acute and past SARS-CoV-2 
infections.
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